This could be reduced with duel MEK inhibition which, alongside anti-PD-1 ICB immunotherapy, promoted T-cell infiltration, intertumoural IFN-γ, improved cytotoxicity and tumour regression [177]. Here, MAP2K7 is linked to neoplasm.